Insys Therapeutics Inc(NASDAQ:INSY) continued to plunge Wednesday after the company announced first-quarter results that came up short of analysts’ expectations. Insys reported earnings of 23 cents a share, which was less than the consensus estimate of 28 cents a share. Revenue totaled $41.6 million, which was short of the consensus estimate of $45.63 million. Insys Therapeutics Inc(NASDAQ:INSY) net profit margin is 40.60% and weekly performance is -41.85%. On last trading day company shares ended up $23.01. Analysts mean target price for the company is $62.00. Insys Therapeutics Inc(NASDAQ:INSY) distance from 50-day simple moving average (SMA50) is -44.98%.
BG Medicine, Inc. (NASDAQ:BGMD) reported financial results for the first quarter ended March 31, 2014. The Company reported net loss for the quarter of $2.2 million, a 60% improvement from the $5.4 million net loss reported in the prior year quarter, on total revenues of $739 thousand versus total revenues of $888 thousand in the first quarter of 2013. BG Medicine, Inc. (NASDAQ:BGMD) shares fell -19.69% in last trading session and ended the day on $1.02. BGMD Gross Margin is 65.90% and its return on assets is -97.50%. BG Medicine, Inc. (NASDAQ:BGMD) quarterly performance is -13.56%.
Enzymotec Ltd (NASDAQ:ENZY) reported financial results for the first quarter ended March 31, 2014. First quarter net revenues (equity method) increased 29.1% to $17.9 million. First quarter net revenues (proportionate consolidation method) increased 43.5% to $23.7 million. First quarter gross margin (equity method) increased over 1,400 basis points to 61.6%. First quarter net income increased 118.0% to $5.1 million. First quarter net income includes approximately $0.4 million of secondary offering related expenses and also includes license amortization expenses related to the settlement and license agreement signed with Neptune. Enzymotec Ltd (NASDAQ:ENZY) shares fell -32.02% in last trading session and ended the day on $13.75. ENZY Gross Margin is 50.60% and its return on assets is 9.30%. Enzymotec Ltd (NASDAQ:ENZY) quarterly performance is -46.29%.
On May 13, Idera Pharmaceuticals Inc (NASDAQ:IDRA) reported its financial and operational results for the quarter ended March 31, 2014. The Company’s clinical focus has now evolved to center on patients with genetically defined forms of B-cell lymphoma and on patients with rare autoimmune diseases. Net loss applicable to common stockholders for the three months ended March 31, 2014 was $9.1 million, or $0.12 per diluted share, compared to a net loss applicable to common stockholders of $4.1 million, or $0.15 per diluted share, for the same period in 2013. There was nominal revenue recognized in the first quarter of 2014 and 2013. Idera Pharmaceuticals Inc (NASDAQ:IDRA) shares moved down -6.38% in last trading session and was closed at $2.64, while trading in range of $2.60 – $2.74. Idera Pharmaceuticals Inc (NASDAQ:IDRA) year to date (YTD) performance is -42.98%.
Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) announced its first quarter results on Mar 7. Since then, share prices have however recovered 3.3%. Achillion reported a first quarter 2014 loss of 17 cents per share, in line with the Zacks Consensus Estimate but wider than the loss of 14 cents recorded in the first quarter of 2013. Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) ended the last trading day at $2.70. Company weekly volatility is calculated as 8.43% and price to cash ratio as 2.14.